Oncology Drug Insights by OmicsX
No Result
View All Result
  • Login
  • Register
  • Home
  • Big Pharma
  • Startups
  • Onco Drug Developers
  • Bio Partnering
  • Finance
PRICING
SUBSCRIBE
  • Home
  • Big Pharma
  • Startups
  • Onco Drug Developers
  • Bio Partnering
  • Finance
No Result
View All Result
Oncology Drug Insights by OmicsX
No Result
View All Result

Pre-Clinical Stage Monoclonal Antibodies in Active Development – 2021

Monoclonal Antibody Name, Target, Developer, Partner, Highest Phase of Development, NCT Number, Cancer Indications etc.

in Drug Targets, Monoclonal Antibodies, Oncology, Pipeline
Home Oncology Biologics Monoclonal Antibodies

Monoclonal Antibody Name, Target, Developer, Partner, Highest Phase of Development, NCT Number, Cancer Indications etc.

Support authors and subscribe to content

This is premium stuff. Subscribe to read the entire article.

Login if you have purchased

Subscribe

Gain access to over 500+ Updated Articles covering Market Research & Analysis on Drug Development.
Subscribe

Buy Single Article

Unlock this Article and Gain Permanent Access to Read it.
Purchase This Article
Share201Tweet126SendShare35
Previous Post

Clinical Stage Monoclonal Antibodies in Active Development – 2021

Next Post

Clinical Stage Bispecific Antibodies in Active Development – 2021

Next Post
Pre-Clinical Stage Monoclonal Antibodies in Active Development – 2021

Clinical Stage Bispecific Antibodies in Active Development - 2021

Oncology Drug Insights by OmicsX

Mapping Bio-Innovations

updated.. easy.. precise... complete...

Presenting filtered comprehensive information. Gain more insights on emerging bio-business, frame strategies, grow faster & better connect with biological science community.

LEARN MORE »

  • Trending
  • Comments
  • Latest
Approved Monoclonal Antibodies for Cancer Treatment

Approved Monoclonal Antibodies for Cancer Treatment

May 30, 2022
Approved Oncology Targeting Small Molecule Kinase Inhibitors

Approved Oncology Targeting Small Molecule Kinase Inhibitors

May 30, 2022

Kinase Inhibitors in Preclinical Development – 2021

May 30, 2022

Early-Stage Cancer Drug Developers Developing Kinase Inhibitors – 2023

March 9, 2023

Early-Stage Cancer Drug Developers Developing Kinase Inhibitors – 2023

Hoffmann-La Roche – Oncology Drug Pipeline Insights – June 2021

Hoffmann-La Roche –
Oncology Drug Pipeline Insights – June 2021

AbbVie, Inc. – Oncology Drug Pipeline Insights – June 2021

AbbVie, Inc. –
Oncology Drug Pipeline Insights – June 2021

Amgen, Inc.  Oncology Drug Pipeline Analysis – June 2021

Amgen, Inc.
Oncology Drug Pipeline Analysis – June 2021

Late-Stage Active Oncology Drug Developers | An Overview

June 22, 2024

South America – Early-Stage Active Oncology Drug Developers

March 9, 2023

Australia & New Zealand – Early-Stage Active Oncology Drug Developers

March 9, 2023

South Korea – Early-Stage Active Oncology Drug Developers | Asia (Part 4)

March 9, 2023

Developed by OmicsX. The entirety of this site is protected by copyright © 2010–2021 HH BioTechnologies Private Ltd.

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

*By registering into our website, you agree to the Terms & Conditions and Privacy Policy.
All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Subscription
  • Category
    • Opinion
    • Tech
  • Landing Page
  • Buy JNews
  • Support Forum
  • Pre-sale Question
  • Contact Us

Developed by OmicsX. The entirety of this site is protected by copyright © 2010–2021 HH BioTechnologies Private Ltd.

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.
Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?

Dynamic title for modals

Are you sure?

Please confirm deletion. There is no undo!